16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA

BE0009727ProteinMycobacterium tuberculosis (strain ATCC 25618 / H37Rv)tlyA

Acts as a host evasion factor, that significantly contributes to the pathogenesis of M.tuberculosis by modulating adaptive immune responses by inhibiting host-protective Th1 and Th17 cytokine responses as well as autophagy (PubMed:25847237). It is acted on by 2 drugs in DrugBank.

Gene name
tlyA
UniProtKB entry
P9WJ63Swiss-Prot
Cellular location
Cytoplasm
Residues / weight
268 residues · 28,074 Da
Also known as
16S rRNA (cytidine1409-2'-O)-methyltransferase · 2.1.1.226 · 23S rRNA (cytidine1920-2'-O)-methyltransferase · Hemolysin TlyA

Resolves to

Protein
UniProtP9WJ63UniProt nameTLYA_MYCTU
Gene
NCBI Gene885396
Pharmacology
KEGGmtu:Rv1694
Structure
PDB5KS2PDB5KYG
Drugs

What you can answer from here — as of September 07, 2019

2DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
10GO termsFunction, process and component, as structured annotations
Sign in
2Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
13+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In